The agreement calls for the purchase of all of the assets of LXT for $125,000 in cash, cancellation of $125,000 in promissory notes held by the two principals of LXT in favor of JMAR and 180,000 shares of JMAR common stock, with future payment rights based on future sales of BioSentry products.
"This acquisition is an important step in JMAR's business expansion process," commented Ronald A. Walrod, CEO of JMAR Technologies. "LXT brings to JMAR more than forty years combined experience in the water industry, including multiple projects involving water testing and security systems. LXT is also a pioneer in adapting light-scattering technologies that can detect and classify waterborne pathogens."
JMAR said the acquisition is expected to close in January, and that the first BioSentry units are expected to be produced in early 2005.
For more information, visit: www.jmar.com